Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
SG Americas Securities LLC lowered its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 73.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,548 shares of the company’s stock after selling 52,878 shares during the quarter. SG Americas Securities LLC’s holdings in Omnicell were worth $1,701,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Omnicell by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,752,906 shares of the company’s stock worth $615,453,000 after purchasing an additional 12,413 shares in the last quarter. Macquarie Group Ltd. lifted its position in shares of Omnicell by 12.5% in the second quarter. Macquarie Group Ltd. now owns 1,218,279 shares of the company’s stock valued at $138,579,000 after acquiring an additional 135,360 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of Omnicell by 1.2% in the second quarter. Clearbridge Investments LLC now owns 1,150,473 shares of the company’s stock valued at $130,866,000 after acquiring an additional 13,809 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of Omnicell by 1,045.9% in the second quarter. Lazard Asset Management LLC now owns 884,541 shares of the company’s stock valued at $100,616,000 after acquiring an additional 807,348 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Omnicell by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock valued at $109,901,000 after acquiring an additional 4,839 shares in the last quarter.
Insiders Place Their Bets
In other Omnicell news, EVP Scott Peter Seidelmann sold 945 shares of the firm’s stock in a transaction on Tuesday, December 27th. The stock was sold at an average price of $48.28, for a total transaction of $45,624.60. Following the completion of the sale, the executive vice president now owns 29,788 shares of the company’s stock, valued at $1,438,164.64. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Randall A. Lipps sold 2,500 shares of Omnicell stock in a transaction on Thursday, December 1st. The stock was sold at an average price of $50.78, for a total value of $126,950.00. Following the completion of the sale, the chief executive officer now directly owns 88,348 shares of the company’s stock, valued at $4,486,311.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Scott Peter Seidelmann sold 945 shares of Omnicell stock in a transaction on Tuesday, December 27th. The shares were sold at an average price of $48.28, for a total value of $45,624.60. Following the completion of the sale, the executive vice president now directly owns 29,788 shares of the company’s stock, valued at $1,438,164.64. The disclosure for this sale can be found here. Insiders sold a total of 9,674 shares of company stock valued at $476,839 over the last quarter. 2.76% of the stock is owned by insiders.
Omnicell Price Performance
OMCL stock opened at $57.06 on Friday. The business has a fifty day moving average of $50.52 and a two-hundred day moving average of $81.02. The company has a quick ratio of 1.86, a current ratio of 2.25 and a debt-to-equity ratio of 0.50. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of 55.94, a price-to-earnings-growth ratio of 5.15 and a beta of 0.89. Omnicell, Inc. has a 52-week low of $46.11 and a 52-week high of $166.12.
Omnicell (NASDAQ:OMCL – Get Rating) last posted its earnings results on Wednesday, November 2nd. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.04. The company had revenue of $348.06 million during the quarter, compared to analysts’ expectations of $362.72 million. Omnicell had a return on equity of 9.74% and a net margin of 3.67%. As a group, research analysts anticipate that Omnicell, Inc. will post 1.62 earnings per share for the current year.
Analyst Ratings Changes
Several equities analysts have recently weighed in on OMCL shares. BTIG Research decreased their target price on Omnicell from $160.00 to $75.00 and set a “buy” rating on the stock in a research report on Thursday, November 3rd. KeyCorp decreased their target price on Omnicell from $130.00 to $75.00 and set an “overweight” rating on the stock in a research report on Thursday, November 3rd. JPMorgan Chase & Co. decreased their target price on Omnicell from $140.00 to $57.00 and set a “neutral” rating on the stock in a research report on Friday, November 18th. Craig Hallum reduced their price objective on Omnicell from $185.00 to $75.00 in a research report on Thursday, November 3rd. Finally, SVB Leerink reduced their price objective on Omnicell from $117.00 to $54.00 and set a “market perform” rating on the stock in a research report on Thursday, November 3rd. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $82.11.
About Omnicell
(Get Rating)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Articles
- Get a free copy of the StockNews.com research report on Omnicell (OMCL)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omnicell, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Omnicell wasn’t on the list.
While Omnicell currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat’s analysts have just released their top five short plays for January 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Enter your email address below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
